Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently
needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and …

Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic
cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving …

Pancreatic cancer is one of the deadliest human malignancies and little progress has been
achieved in its treatment over the past decades. Advances in our understanding of the …

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer
therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which …

Purpose: Improved therapeutic approaches are needed for the treatment of pancreatic
ductal adenocarcinoma (PDAC). As dual MEK and PI3K inhibition is presently being used in …

Standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC), nab-paclitaxel
(NPT) plus gemcitabine (Gem), has led to an average survival of 8.5 months. Presently, no …

Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is
rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, metastatic disease with
limited treatment options. Factors contributing to the metastatic predisposition and therapy …

Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …

Over 90% of pancreatic cancers present mutations in KRAS, one of the most common
oncogenic drivers overall. Currently, most KRAS mutant isoforms cannot be targeted directly …